

0001178913-25-0003186-K TRINITY BIOTECH PLC 2025020420250204083638083639083639 0 0001178913-25-000318 6-K 1 20250204 20250204 20250204 TRINITY BIOTECH PLC 0000888721 2835 000000000 L2 1231 6-K 34 000-22320 25585468 IDA BUSINESS PARK, BRAY, CO WICKLOW IRELAND DUBLIN IRELAND L2 18 01135312955111 3 ROCK ROAD SANDYFORD INDUSTRIAL ESTATES DUBLIN IRELAND L2 18 6-K 1 zk2532651.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 TRINITY BIOTECH PLC (Name of Registrant) IDA Business Park Bray, Co. Wicklow, Ireland (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): No Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): No Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070) and Registration Statements on Form F-3 (File Nos. 333-239701, 333-264992 and 333-267160). DUBLIN, Ireland (February 04, 2025) - Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided a positive update on funding by the U.S. government for HIV testing programs that utilize the Company's two rapid HIV tests. The Company welcomes reports that on February 1, 2025, the U.S. Department of State issued a memo confirming that a waiver providing for continued funding for HIV testing under the President's Emergency Plan for AIDS Relief (PEPFAR) was authorized pursuant to the 28 January 2025 waiver issued by the Secretary of State. The waiver relates to a pause in foreign aid pursuant to the U.S. President's Executive Order on Reevaluating and Realigning United States Foreign Aid. Other testing programs that utilize the Company's two rapid HIV tests have been largely or wholly unaffected by the President's Executive Order. Trinity Biotech looks forward to continuing to work with its HIV testing partners in supporting HIV testing efforts under the PEPFAR and other programs.

Forward-Looking Statements This filing includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Trinity Biotech's cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the company's distributors, losses or system failures with respect to Trinity Biotech's facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech's products and services, the continuing development of its products, required government approvals, continuing international government financial support for healthcare programs, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech's intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under "Risk Factors" in Trinity Biotech's annual report on Form 20-F for the fiscal year ended December 31, 2023 and Trinity Biotech's other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/ Louise Tallon Louise Tallon Chief Financial Officer Date: February 4, 2025